ID: MRFR/Pharma/0324-CR | July 2019 | Region: Global | 101 pages
The Global Ticagrelor Market is expected to register a CAGR of 9.00% and is anticipated to reach USD 2554.39 Million by 2027.
Ticagrelor is an anti-platelet drug which decreases the platelet aggregation and prevents blood clots. Ticagrelor works by binding to the P2Y12 in a unique manner and inhibits the adenosine diphosphate (ADP) signaling by locking the receptor and makes it inactive. This hinders the platelet aggregation and reduces blood clots, thereby reducing the risk of acute coronary syndrome (ACS).
The increasing cardiovascular rate is eventually driving the growth of the ticagrelor market and rise in the older population has a direct effect on the ticagrelor market, as the older population is more prone to injuries and other health conditions, are the major drivers propelling market growth. However, Ticagrelor causes bleeding that can be serious and sometimes leads to death, constrain the growth of the market.
Cardiovascular disorders are heart conditions that include diseased vessels, structural problems, and blood clots. Ticagrelor drugs used in the treatment of cardiovascular disorders interfere with blood coagulation by inhibiting platelet aggregation. In acute coronary syndrome, the combination of ticagrelor and aspirin is reported to have reduced the prevalence of vascular deaths and myocardial infarctions more than the combination of clopidogrel and aspirin. For instance, according to the American Heart Association, in 2014, around 31% of the deaths in the US were due to cardiovascular disorders.
Similarly, as per the American Heart Association, approximately USD 555 billion was spent in the Americas for the treatment of cardiovascular disorders. Moreover, the increasing aging population is likely to positively affect market growth, thus spurring the demand for the ticagrelor market. Additionally, the increasing occurrences of obesity are expected to fuel the cardiovascular patient pool indirectly, thus encouraging the demand for the ticagrelor market. On the other hand, the high bleeding complications of ticagrelor is anticipated to hamper the market growth.
Global Ticagrelor Market Size, by End User, 2017 (USD Million)
Source: MRFR Analysis
The global ticagrelor market has been segmented into dosage (Mg), route of administration, application, and end user. By dosage (Mg), the market has been segmented 90 mg and 60 mg. Based on the route of administration, the market has been segmented into the oral and nasogastric tube. Based on application, the market has been bifurcated into acute coronary syndrome and heart surgeries. Heart surgeries are further divided into angioplasty, stent placement, and coronary artery bypass graft. By end user, the market has been segmented into hospitals and clinics and ambulatory centers. The hospitals and clinics segment accounted for a market value of USD 522.03 million in 2017.
The player in the global ticagrelor market is AstraZeneca, PLC.
Asia-Pacific Ticagrelor Market Share, by Country, 2017 (%)
Source: MRFR Analysis
The global ticagrelor market, based on region, is divided into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas is estimated to dominate the global ticagrelor market during the forecast period. This is attributed to its sustainable growth in GDP per capita income and the rising geriatric population highly prone to degenerative diseases and chronic illnesses, which have caused an increased verge of diagnosis and therapeutics. The European market for ticagrelor is expected to be the second-largest during the forecast period. The rising patient population of strokes and cardiovascular disorders, increasing research on antiplatelets, availability of advanced treatment facilities, increasing healthcare expenditure, and introduction of advanced and integrated treatment options into the market along with the presence of good healthcare infrastructure is expected to boost the growth of the market in this region. Asia-Pacific is estimated to be the fastest-growing market due to the increasing per capita disposable incomes along with government initiatives to enhance the quality of healthcare. In addition to this, rising cardiovascular diseases being the primary concern in this region. Moreover, in the Asia-Pacific region, China accounted for a market share of 28.0% in 2017. Furthermore, the market in the Middle East & Africa is expected to witness steady growth due to limited access to healthcare facilities.
No recent critical developments regarding the market.
Global Ticagrelor Market, by Dosage (MG)
Global Ticagrelor Market, by Route of Administration
Global Ticagrelor Market, by Route of Application
Global Ticagrelor Market, by End User
Global Ticagrelor Market, by Region
Available Additional Customizations
Frequently Asked Questions (FAQ) :
Ticagrelor market projected to grow at approximately 9% CAGR during the assessment period (2018-2027).
The valuation of the global ticagrelor market is estimated to increase to USD 2554.39 MN by the end of 2027.
Large patient pool suffering from heart problems and increasing product development, commercialization, and improving funding for R&D by the market players are major tailwinds pushing the growth of the global ticagrelor market.
North America holds the largest share in the global ticagrelor market, followed by Europe and the Asia Pacific, respectively.
AstraZeneca, Eli Lilly, Boehringer, Ingelheim, Pfizer, Amgen, Merck, Roche, GSK, Boehringer, Alexion, and Amgen, are some of the top players operating in the global ticagrelor market.
Global Ticagrelor Market - Summary
Ticagrelor is an oral drug which prevents blood clots and reduces the probability of stroke and heart attack in patients with heart disorders. It is commercialized under the names of Possia, Brilique, and Brilinta. The drug is an anti-platelet medication which got approval by the U.S. Food and Drug Administration (FDA) in 2011. Its applications have extended to treat sickle cell disease, percutaneous coronary intervention (PCI), and acute coronary syndrome (ACS).
The global ticagrelor market is expected to reach a valuation of USD 2,554.39 million by 2027. It can register a 9% CAGR over the forecast period (2018-2027) to reach the benchmark. Increasing prevalence of cardiovascular disorders in Europe and North America is likely to boost the demand for the drug. In addition, its success in clinical trials, high effectiveness over clopidogrel, and its approval in more than 100 countries can boost the market growth till 2027.
The expanding geriatric populace is another driver of the ticagrelor market. Prevalence of chronic diseases and their susceptibility to these due to low immunity levels can positively impact market growth. In addition, growth opportunities for the market exist due to demand for anti-platelet drugs in the treatment of sickle cell disease and transient ischemic disease.
Dosages of the drug available in the ticagrelor market are 60 mg and 90 mg. The 90 mg segment accounted for a large market share and predicted to dominate till the end of the forecast period. Its primary use in the treatment of acute coronary syndrome (ACS) can be attributed to its success over its counterpart. On the other hand, the 60 mg segment can accrue significant revenue for the ticagrelor market owing to its indication in heart patients. This is supported by evidence unearthed in the Phase 3 PEGASUS-TIMI 54 study by AstraZeneca. The study showed heart patients having a reduced probability in deaths by cardiovascular disease when the drug is taken in combination with low-dose aspirin.
Two routes of administration described include oral and nasogastric tube. Oral segment has captured a large share of the ticagrelor market and will continue to be the dominant segment out of the two. But the nasogastric tube segment is likely to generate significant revenue owing to rising numbers of bedridden patients with dysphagia.
Applications of the drug include heart surgeries and acute coronary syndrome. Acute coronary syndrome can induce massive demand for the ticagrelor market owing to high prevalence of cardiac disorders. On the other hand, heart surgeries can induce the demand for the drug owing to its ability to prevent clots.
Market end-users include hospitals & clinics, ambulatory centers, and others. Hospitals & clinics are touted to be the primary end-users of ticagrelor owing to the healthcare institution being a trusted source of diagnosis and treatment of ACS. Anti-platelet drugs are known to prevent cardiac arrests and strokes in patients with PCI. On the other hand, ambulatory centers have experienced the efficacy of the drug which reduces the chances of ischemic heart attacks 24 hours after PCI on administration.
Geographic segmentation of the ticagrelor market reveals details regarding Americas, Europe, Asia Pacific (APAC), and Rest-of-the-World (RoW).
The Americas is expected to dominate the market till the end of the forecast period owing to massive healthcare expenditure dedicated by the nations of the U.S. and Canada to curb mortality rates linked to cardiovascular diseases. Europe, on the other hand, is expected to assume the second position in ticagrelor market owing to investments in anti-platelet therapy treatments and high incidence of strokes and cardiovascular disorders. The APAC region has a wide ambit for the ticagrelor market owing to the large patient pool and supportive healthcare policies in Australia, India, and China.
The ticagrelor market is monopolistic in nature with a single player controlling its production and manufacture, AstraZeneca plc. It has decided to protect itself from patent infringement by preventing other drug manufacturers from creating generics. Development of the drug in clinical trials has proven successful with it being approved for treating medical conditions other than strokes.
AstraZeneca is the sole manufacturer of Brilinta (generic: ticagrelor) an “anti-platelet” medication that helps prevent stroke or serious heart problems in patients who have had a heart attack or severe chest pain (angina). The drug works by preventing platelets in the blood from sticking together and forming a blood clot. Brilinta by AstraZeneca was approved by the US Food & Drug Administration (FDA) in July 2011.
The Brilinta 90 mg dosage form by AstraZeneca has been approved in over 100 countries and is included in 12 major acute coronary syndrome (ACS) treatment guidelines globally. Additionally, Brilinta 60mg is approved in over 60 countries for the long-term prevention of death from cardiovascular diseases, heart attack, and stroke for patients with a history of heart attack. AstraZeneca is strongly engaged in growth strategies in order to promote its product across the globe. For instance, in June 2017, the China Food and Drug Administration (CFDA) approved Brilinta 60 mg tablets for patients with a history of heart attack. Subsequently, in July 2017, the Ministry of Human Resources and Social Security agreed to add Brilinta 90 mg to the National Reimbursable Drugs List (NRDL). Similarly, in August 2017, AstraZeneca presented Phase III trial data (PEGASUS-TIMI 54) at the Annual Congress of the European Society of Cardiology (ESC) in Barcelona, Spain. These approvals and presentations are paving a way for the positive growth for Brilinta all over the globe.
The firm has also been focusing on diversifying the applications of Brilinta. For instance, the application of Brilinta in the prevention of vaso-occlusive crises in pediatric patients with sickle cell disease is under investigation. Additionally, the use of Brilinta in patients with type 2 diabetes and coronary artery disease without a previous history of myocardial infarction (MI) or stroke is also been studied. These wide applications of Brilinta are driving the growth of the ticagrelor market.
AstraZeneca has so far been the only provider of ticagrelor and has been accused of prolonging monopoly of the product beyond its legitimate patent life. The firm has been trying to withhold its market presence in the antiplatelet segment by applying for multiple patents. AstraZeneca has filed various lawsuits against firms that have been trying to enter the ticagrelor market by manufacturing generics of Brilinta. For instance, AstraZeneca has filed a lawsuit in the Delhi High Court against the Indian drug maker, Dr. Reddy’s Laboratories to block it from launching generic versions of Brilinta, AstraZeneca’s blockbuster medicine for heart ailments. Additionally, AstraZeneca filed similar lawsuits against Natco Pharmaceuticals and Micro Labs in the early months of 2018 and has blocked both the companies from launching copies of Brilinta.